Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 12Supratentorial Neoplasms 2Meningioma 2Delirium 2Stroke 1Spinal Cord Neoplasms 1Seizures 1Pain, Postoperative 1Pain 1Neuroinflammatory Diseases 1Neurofibromatosis 1 1Neurocognitive Disorders 1Neoplasms 1Hypoxia 1Hemorrhage 1Glioma 1Glioblastoma 1Epilepsy 1Emergence Delirium 1Central Nervous System Vascular Malformations 1Central Nervous System Diseases 1Arteriovenous Malformations 1Aneurysm 1

Interventions

Temozolomide 1Sodium Chloride 1Saline Solution 1Radiotherapy 1Injections 1Ferrosoferric Oxide 1Dexmedetomidine 13-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × Saline Solution × CNS × Clear all
NCT04266665 2026-03-25

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

Aristotle University Of Thessaloniki

Phase 4 Completed
56 enrolled
CNS

Neuroinflammatory Diseases, Hypoxia, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡